Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00148382

Enrollment

Registered

2005-09-08

Start date

2005-04-30

Completion date

2005-07-31

Last updated

2007-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Pharmacokinetics, Pharmacodynamics

Brief summary

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Detailed description

Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.

Interventions

DRUGATL-962

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Obese, otherwise-healthy subjects * Body mass index 30-45kg/m2

Exclusion criteria

* Women who are pregnant or breast feeding * Any drug treatment within 2 weeks of commencement of dosing in this study

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of metabolites of ATL-962	—

Secondary

Measure	Time frame
Effect of ATL-962 on faecal fat excretion	—
Safety and tolerability of ATL-962	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026